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Abstract
Background: Current NHS policy encourages an integrated approach to provision of mental and 
physical care for individuals with long term mental health problems. The ‘PARTNERS2’ complex 
intervention is designed to support individuals with psychosis in a primary care setting.
Aim: The trial will evaluate the clinical and cost- effectiveness of the PARTNERS2 intervention.
Design & setting: This is a cluster randomised controlled superiority trial comparing collaborative 
care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary 
care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP 
practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care 
(‘intervention’); or (b) standard care only (‘control’).
Method: PARTNERS2 is a flexible, general practice- based, person- centred, coaching- based 
intervention aimed at addressing mental health, physical health, and social care needs. Two hundred 
eligible individuals from 39 GP practices are taking part. They were recruited through identification 
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from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary 
outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process 
evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and 
look for unintended consequences. An economic evaluation will estimate its cost- effectiveness. 
Intervention delivery and follow- up have been modified during the COVID-19 pandemic.
Conclusion: The overarching aim is to establish the clinical and cost- effectiveness of the model for 
adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.
How this fits in
The current NHS Community Mental Health Transformation policy (NHS England 2019) aims to ensure 
all those with psychosis and a need for care are supported, and for much of this to be carried out 
as a collaboration between primary care and third sector organisations. Previously, the policy focus 
was specialist mental health care via community teams and then discharge to primary care for those 
with less, but often still significant, need, thus presenting a significant divide between primary and 
secondary care. The authors have completed 2.5 years of preparatory work to understand the nature, 
strengths, and limitations of the current status of primary–secondary care collaboration and, alongside 
service users, have developed and piloted a primary care- based collaborative care model. PARTNERS2 
is the first trial of that model to be carried out in the UK.
Table 1 Programme and trial phases and timelines
Stage and key aims Duration Key dates
Develop feasibility stage
Aims:
To develop and refine the intervention 
model
To agree outcome measures
To test recruitment processes
24 months 2014–2016
Randomised controlled trial: internal pilot
Aims:
To further test feasibility of both recruitment 
and the intervention delivery for patients 
and GP practices.
To assess recruitment against objectives:
• GP practice recruitment rates – 8 GP 
practices per site (24 total)
• Participant eligibility rates – 24 
participants per site (72 total)
To assess delivery and safety of 
intervention—for example, intervention 
delivery (care partners in place) and adverse 
events such as crisis care (home treatment 
teams), and admissions (psychiatric).
To review initial sample size target of 336 
participants
6 months Trial started: 1/10/2017
Trial registered: 16/10/2017
First participant recruited: 8/6/2018
RCT (completion of RCT following 
internal pilot):
Aim:
To establish the clinical and cost- 
effectiveness of primary care based 
collaborative care for people with a clinical 
diagnosis of schizophrenia, bipolar, or other 
types of psychosisa
Completion of recruitment
Follow up: 10–12 months
Recruitment end date: 28/2/2020
Follow up end: 28/12/2020
Data collection end date:
31/3/2020
Study end date: 30/04/2021
a Revised recruitment target of 204 participants with a diagnosis of schizophrenia, bipolar, or other types of psychosis from 
~34 clusters (GP practices), based on prespecified sample size recalculation (December 2019) and funder requirements 
(January 2020).
RCT = Randomised controlled trial.
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Introduction
This article presents the protocol (version 7.3, 18.08.2020) for the PARTNERS2 (develoPing 
intergrAted primaRy care for paTieNts with sERiouS mental illness) cluster randomised controlled 
trial (RCT) to assess the clinical and cost- effectiveness of a primary care- based collaborative care 
model for people with diagnoses of schizophrenia, bipolar, or other psychoses. Such individuals are 
recognised as having considerable unmet physical, emotional, and social needs.1 The current NHS 
Community Mental Health Transformation policy (NHS England 2019) aimed to ensure all those with 
psychosis and a need for care are supported, and for much of this to be carried out as a collaboration 
between primary care and third sector organisations. Previously, the policy focus was specialist mental 
health care via community teams and then discharge to primary care for those with less, but often still 
significant, need, thus presenting a significant divide between primary and secondary care.
PARTNERS1, which ran during this previous policy, found that nearly a third of people in the UK 
with a diagnosis of schizophrenia, bipolar, or other psychoses were seen only in primary care.1 Poor 
continuity of care and lack of information exchange between primary and secondary care created 
barriers to effective support. To overcome these challenges, the PARTNERS model was developed to 
improve collaboration between secondary care, primary care, and the service user.
Feasibility and piloting in the PARTNERS2 programme
Initial phases of PARTNERS2 focused on understanding current care pathways, developing the 
intervention, and addressing trial science questions. Different phases and timescales of the overall 
programme are summarised in Table 1. This protocol was written during the delivery and follow- up 
phase of the trial; use of past and present tense in the paper indicate activities at the time of writing.
A multi- site notes review was carried out to understand the relationship between primary and 
secondary care. The intervention was co- produced by clinical academics, researchers, and people 
with lived experience of ongoing mental health needs. The latter group were engaged through three 
Lived Experience Advisory Panels (LEAPs) advising the programme. The intervention was founded 
on Wagner’s Chronic Care Model,2 principles of personal recovery,3 and coaching for mental health.4 
The programme theory and practice were iteratively developed utilising a realist approach,5,6 wider 
literature, primary data, and stakeholder input.7 The intervention was ‘fixed’ after the refinement in 
this feasibility stage.8
Approaches to recruitment were tested iteratively involving flexibility for non- responders and 
support from NHS employed researchers for pre- consent work (initial identification and approach 
by letter and telephone) in primary care. A core outcome set for use in bipolar disorder trials was 
developed.9 To account for the wider psychosis target population in PARTNERS2 and the nature 
of the intervention, an additional stakeholder consultation was undertaken to select outcomes and 
measures. QoL was selected as the most important outcome domain. Relevant measures of QoL were 
reviewed and the Manchester Short Assessment Quality of Life (MANSA) was selected on the basis 
of being clinically relevant to the target population and as potentially amenable to change by the 
intervention. The MANSA has good validity and reasonable internal consistency.10
Challenges during trial set up, internal pilot, and COVID-19
Health Research Authority guidance changed while planning the trial, which meant that the flexible 
approaches developed during the conduct of the pilot phase were initially not permitted due to 
confidentiality concerns. Some components (for example, practices supported in pre- consent 
identification and approaches by NHS- employed researchers) were reinstated following Health 
Research Authority amendments once recruitment was shown to be slow. Changing circumstances in 
host NHS Trusts and delays in trial set- up led to withdrawals from the study of one trust during set- 
up, and the Lancashire Care Foundation Trust during the early phase of recruitment, resulting in the 
need to identify new host trusts. Although not all recruitment targets had been met, recruitment in 
two trusts (Cornwall and Plymouth) had been shown to be successful, and thus the trial was continued 
pending a delayed sample size review carried out in late 2019. As detailed in Table 1, this review 
led, in December 2019, to the recommendation from the trial oversight groups (Data Monitoring 
Committee [DMC] and Trial Steering Committee [TSC]) for a reduction of the original sample size. 
In January 2020, the funder requested recruitment to stop in order to complete the trial within the 
funding envelope and with a change in power (see sample size section below).
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Soon after recruitment had closed, and partway through intervention delivery and follow- up data 
collection, the COVID-19 pandemic and national lockdown in the UK (March 2020) had a sudden 
impact on the trial. In consultation with the TSC and funder, the research team adapted methods for 
intervention delivery, follow- up data collection, and the ongoing process evaluation. These adjustments 
are outlined in Table 2. The adapted methods were tested for an 8- week period. In light of the success 
of this adaption, the continued uncertainty surrounding the pandemic, and risk assessments for both 
service users and practitioners, the decision was made to continue remote delivery, where possible, of 
both the intervention and follow- up, and process evaluation data collection until the end of the trial. 
Face- to- face delivery and data collection were used when safe and preferred by participants.
Method
Objectives
The PARTNERS2 cluster RCT tests a collaborative care model for people diagnosed with bipolar, 
schizophrenia, and other forms of psychosis in addition to modified usual care, in comparison with 
usual care alone. The trial aims to understand the benefits of refocusing mental healthcare for the 
target group into primary care through provision of a coaching- based collaborative model to assist 
individuals with their recovery. The primary hypothesis is intervention arm participants will have 
improved QOL compared those receiving usual care alone.
The secondary hypotheses are that, in comparison with usual care only participants, intervention 
arm participants will have improved:
1. hours per week spent in structured activity;
2. mental health wellbeing;
3. physical healthcare;
4. increased experiences of personal recovery.
An economic evaluation will assess the costs, outcomes, and relative cost- effectiveness of the 
intervention (see Health economics evaluation section below). The study includes a comprehensive 
mixed- methods process evaluation to assess fidelity to the model, test the programme theory, and 
gain a more in- depth understanding of the intervention in practice in relation to implementation 
barriers and facilitators.
Patient and public involvement
Several different patient and public involvement approaches are embedded into the trial design. 
The independent steering group and the DMC have patient and carer members. The study sites all 
recruited local LEAPs and service user posts were created, coordinated by The McPin Foundation. 
This means that many aspects of the trial have been shaped by expertise from experience, as follows:
• The original research design and research question was co- designed with patients, including a 
co- applicant.
Table 2 Adjustments to the trial due to COVID-19 restrictions (8- week trial phase)
Challenges Solutions
Adapting the intervention to remote 
delivery
Delivery via telephone or video conferencing software. Intervention practitioners received training on 
using video conferencing software and delivering interventions remotely. Coaching and goal- setting were 
adjusted to be appropriate to a lockdown environment. The majority of participants found it acceptable 
to continue the intervention after adaption to remote delivery. Practitioners delivering the intervention 
reported they were able to continue collaborating with primary care by remote means.
Collecting data remotely Follow- up data and process evaluation data collected via telephone, video conferencing, or post. For the 
secondary outcome of time use, data collection was adjusted to include activities participants conducted 
remotely, such as attending church via video conferencing.
Understanding the feasibility and 
acceptability of continuing the intervention 
and data collection remotely. This included 
acceptability to participants and the 
feasibility of collaborating with primary 
care.
8- week trial phase, including rapid realist evaluation. This realist evaluation considered: the experiences 
of the intervention practitioners delivering the intervention during COVID-19 restrictions; and during 
routine audio- assisted recall interviews with service users, exploring their experiences of engaging with the 
intervention by remote methods.
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• The intervention and guidance manuals have all been developed and reviewed with the three 
LEAPs. Care partner training was co- designed by the LEAPs. Service user researchers delivered 
elements of this training.
• The trial outcome measures were selected through a sub- study, which also developed a core 
outcome set for bipolar. This involved input from the three LEAPs. Patients and carers were part 
of the final decisionmaking workshop where trial outcomes were agreed.
• The LEAPs met every 3 months. They reviewed all recruitment materials and contributed to 
the development of interview schedules; produced a study specific website with video content 
to aid participant understanding of what taking part would involve; and were kept up- to- date 
throughout via meetings and newsletters. Service user researchers have been involved in recruit-
ment of participants and undertaking other study roles alongside traditionally recruited research 
assistants. The role of the LEAPs and service user researchers in the PARTNERS2 programme is 
the subject of a separate article.11
• Dissemination will include input from the LEAPs. A LEAP- led dissemination event and accessible 
dissemination materials for participants, including a video and infographic, are planned.
Trial design and setting
This is a cluster randomised controlled superiority trial, with randomisation at GP practice level. All 
participants continue to receive their usual care. The trial is registered as ISRCTN 95702682. See 
Table 1 for registration details.
The trial was conducted in GP practice research sites within four English geographical regions: 
Birmingham and Solihull, Cornwall, Plymouth, and Somerset. This represents a varied cross- section of 
society, including urbanity/rurality, and different levels of ethnic diversity.
GP practices were assessed for capacity and capability to deliver the trial. This included willingness 
to physically host the Care Partner, including computer access (key intervention role, see intervention 
description below), and support data collection requirements.
Table 3 Trial entry criteria for research participants
  Inclusion criteria
• Registered with a participating GP practice (with at least six individuals coded as having severe mental 
illness), which refer into recruited community mental health teams, within one of the four region NHS 
Trusts: Birmingham and Solihull Mental Health Foundation Trust, Livewell South West (Plymouth), Cornwall 
Partnership NHS Foundation Trust, or Somerset Partnership NHS Foundation Trust.
• Aged ≥18 years
• A clinical diagnosis of schizophrenia, bipolar, or other types of psychoses
• Evidence for care need in relation to this diagnosis in previous 2 years (automatic for those in secondary care; 
assessed from notes for primary care only).
  Exclusion criteria
• Inability to understand English (or access translation services)
• Inability to give informed consent
• Significant need requiring ongoing secondary multi- disciplinary care (such as those meeting criteria for 
assertive outreach or early intervention functions, and therefore defined as higher, rather than lower, risk or 
need)
• Currently receiving home crisis care or care in an inpatient or secure setting
• Those excluded at the discretion of GPs, if it is felt that inclusion in this trial is not within the best interests of 
their patient
• Currently participating in a cognitive behavioural therapy, or a psychosocial or medicinal trial for psychosis or 
bipolar
• Individuals with a primary diagnosis of dementia receiving secondary care for dementia
• Individuals with a primary diagnosis of learning disability receiving care from secondary care for learning 
disability
• Individuals with ongoing significant and chaotic substance or alcohol misuse, making engagement with trial 
and intervention problematic
CRN = Clinical Research Network. EOI = Expression of Interest. ASAP = As soon as possible.
Plappert H et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2021.0033
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Mental health trust staff search 
for potentially eligible patients 
at the practice seen in 
secondary care. Patients 
checked for eligibility and sent 
to GP practice.
GP practice runs pre-coded search 
to produce list of potentially 
eligible patients. 
List merged with secondary care 
list. Trial ID numbers allocated to 
each. Practice, Trust or CRN staff 
delegated role screen all primary 
care only patients.
All eligible patients sent 
information pack and invite 
letter by practice or CRN staff.
Patients screened in 
secondary care sent ASAP, 
primary care patients sent 
ASAP after GP has 
signed off list.
Patient returns EOI form 










Patient returns EOI form stating 
that they are interested in 
participating
Researcher to contact patient 
via their preferred method of 
contact, provided with long 
participant information sheet 
and asked if they wish to attend 
an appointment
Rapid invite letter sent by 
practice or CRN staff to patients 
who have not returned EOI form 
after 2 weeks
Practice, Trust or CRN staff 








Patient wants to 
participate
Consent and baseline data collectedPatient doesn't 
consent
Once all consent and baseline 






Care Partners to 
commence site set 
up with GP practice
Trial intervention — 10 
months and 2 month 
transition to usual care
10 month follow up data 








Figure 1 Flowchart detailing recruitment of research participants process.
ASAP = as soon as possible. CRN = clinical research network. EOI = expression of interest.
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Study population and recruitment of participants
The study recruited adults with a diagnosis of schizophrenia, bipolar, or other psychoses who either: 
are seen in secondary care and considered to of be lower risk/need; or are seen only in primary care 
(further details in Table 3). Figure 1 provides detail of the recruitment process, outlined below.
Potential participants seen in secondary care were identified from electronic records. Individuals 
were checked for eligibility by experienced secondary care clinicians and suitability confirmed by 
primary care staff. Potential participants seen only in primary care were identified from searches of 
electronic health records that were then checked for eligibility by primary care or clinical research 
network staff.
After eligibility checks, information packs were posted to potential participants who were asked 
to return expressions of interest (or wish to decline). Interested participants were contacted by their 
preferred method. Arrangements to meet at the practice or home were made. They could give 
informed consent either at the initial meeting or at a later point; participants could choose to complete 
baseline measures in multiple meetings.
Non- responders were sent an appointment letter, inviting them to an appointment with a researcher. 
Where capacity allowed, practice or secondary care staff telephoned the participant to remind them 
(maximum of three attempts). The appointment allowed researchers to discuss the study face- to- face; 
if, at the end of the discussion, the potential participant wished to consent to participate in the study 
this could take place a) in the same meeting, if there was time, or b) at an additional meeting if there 
was not.
Participants were provided with a £10 high street shopping voucher and thank you card as a 
gesture of gratitude on completion of each data collection appointment (a total of £20 for baseline 
and follow- up appointments) and for any qualitative interviews. All recruitment documentation was 
designed in consultation with LEAPs.
Randomisation and allocation concealment
Practices were randomised to control and intervention groups on a 1:1 basis, stratified by recruiting 
region and estimated practice psychosis population (small and large), determined by the number of 
adults categorised as MH001 according to the Quality and Outcomes Framework register 2017/18 
(median 70 patients).12 Practices were classified as ‘small’ if the MH001 list was <70 and ‘large’ if ≥70 
adults.
The Clinical Trials Units (CTU) conducted the randomisation procedure. Allocation was concealed 
from participants, researchers, and practices until recruitment was complete within each practice 
(cluster). Researchers then requested unmasking.
After unmasking of a practice, the practice and its participants were informed of the allocation by 
letter, or the participant’s preferred method of contact. For logistical reasons, researchers conducting 
follow- up data collection could not be masked. Those conducting statistical analyses are masked from 
assignment.
Intervention
The PARTNERS service places a trained secondary mental healthcare worker in primary care (a ‘Care 
Partner’). Care Partners work collaboratively with the participant, primary care, secondary care, and 
other organisations, aiming to improve the participant’s QOL, mental health, and physical health care. 
Place and method of contact was flexible, with contact once every 2 weeks at the start, stepping 
down to once every 3 months for some, but stepping up to referral into secondary care if required. 
The manualised model (manual available from authors on request) of person- centred care aims to 
improve the emotional, social, and mental and physical health needs of people with severe mental 
illness (SMI). The Care Partners work with participants to develop a shared understanding and utilise 
coaching techniques with the intention of encouraging participants to:
• Be more confident and proactive about their health through supporting participants to improve 
their self- management skills.
• Achieve personal goals related to their health or other aspects of their lives on their recovery 
journey.
Participants receive the intervention for up to 12 months, including a 2- month transition period 
back to usual care only. Participants on the secondary care caseload remain so for the duration of 
Plappert H et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2021.0033
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the trial. For those receiving the intervention, the intensity of usual care was reduced according 
to a protocol specific to each trust, to the extent that was possible based on their individual risk, 
governance, and Care Programme Approach procedures.
Care Partners are mental health workers with a variety of backgrounds, and include occupational 
therapists, social workers, psychiatric nurses, and support workers. They received 2–3 days initial 
training in the PARTNERS2 collaborative care model, top- up training throughout the study from 
PARTNER2 study team members, and supervision from trained supervisors. Supervisors included 
community mental health team managers, mental health nurses, and psychiatrists who all received 
training in the PARTNERS2 model. GP co- chief investigator (RB) provided cover for supervision during 
periods of illness or absence.
Control group
All participants allocated to the control arm of the trial continue to receive usual care, either within 
primary care only or also with secondary care. This comparator reflects the unmet treatment need that 
the intervention aims to resolve. Such care is proactive in secondary care, but with variable practitioners 
and frequency. Primary care includes an annual review and otherwise tends to be reactive, including 
mental and physical care as clinically indicated.
Outcome measures
The trial primary outcome is QOL at the primary endpoint, as measured by the MANSA. This is a 
self- complete questionnaire comprising both objective and subjective questions across different life 
domains (work and education, personal finances, leisure activities, social life, living situation, family 
life, personal safety, and health). Objective items (for example, employment status) are described 
separately and not aggregated. Satisfaction is rated on a 7- point Likert scale (1 = negative extreme, 
7 = positive extreme) and scorings are processed to provide three different types of results: separate 
domain ratings; an overall MANSA score, assessing QOL (the primary outcome); and a general (single 
item) QOL rating. Staff undertaking data collection were trained in using the measure. The MANSA 
was collected at baseline and follow- up.
Secondary outcome measures were assessed at baseline and follow- up (listed in Table 4). Data 
collection forms are available from the authors on request.
NHS and social care service use for the preceding 3 months prior to baseline and follow- up was 
assessed to estimate service cost. The period of 3 months was chosen to optimise accuracy of recall 
and scope of service use. Data includes:
• outpatient contacts;
• inpatient stays;
• primary care consultations; and
• other health and social care contacts;
The following secondary outcomes were assessed at 10 months only from primary care and 
secondary care records:
• Healthcare monitoring to assess which of the following have been received by the patient within 
their GP practice:
 – annual health check;
 – blood pressure, lipids, glucose assessed, and whether treatment was changed; and
 – lifestyle interventions (for example, smoking cessation, alcohol, and dietary guidance)
• Safety variables:
 – number of crisis care episodes and days under home treatment; and
 – mental health admissions and number of days’ inpatient;
COVID-19 sub-study
Participants who experienced COVID-19 restrictions during their involvement in the study in both 
arms are asked additional questions at follow- up. This capitalises on the opportunity to understand 
how lockdown has impacted on the participants’ mental health, access to physical health care, and the 
impact of social distancing on usual activities.
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Retention
Researcher rapport, flexibility in contact, and thank you vouchers were used to enhance retention. 
Where participants withdraw from either the intervention or the study, reasons for withdrawal will be 
captured via quantitative and qualitative data where possible.
Sample size
The initial sample size for the full trial was based on detecting a mean between- group difference of 
0.45 points in the overall MANSA score. Assuming a standard deviation (SD) of 0.90, this is equivalent 
to detecting half a SD. This standardised effect size corresponds to a medium to large effect size, and 
in line with the target difference for the DIALOG+ trial.13
To detect this target difference, and assuming SD of 0.90, coefficient of variation of cluster size 
of 0.74 and intra- cluster correlation of 0.05, the recruitment target for the full trial was originally 336 
Table 4 Schedule of assessment for practices and participants





  Eligibility check x     
  Valid informed consent x x   x
Data to inform if full- scale RCT is feasible
  Practice recruitment rates x x x x
  Practice withdrawal rates     x x
  Participant eligibility rates x x x x
  Patient recruitment rates   x x   
  Participant withdrawal rates     x x
Outcome measures
  Quality of life (MANSA)   x   x
  Time use (ONS Time Use Survey)   x   x
  Personal recovery: questionnaire 
about the process of recovery (QPR-
15)
  x   x
  General health status and quality 
adjusted life years: EuroQol (EQ- 5D- 
5L)
  x   x
  Mental wellbeing: Warwick–Edinburgh 
mental wellbeing scale
  x   x
  Capability measure and quality 
adjusted life years: ICEpop capability 
measure
  x   x
  NHS resource use: records audit and 
economic interview
      x
  Experience of care: brief INSPIRE   x   x
  Healthcare monitoring       x
Safety variables     
  Admissions (psychiatric)       x
  Crisis care (home treatment)       x
Process evaluation   x   x
Impact of COVID-19       x
MANSA = Manchester short assessment quality of life. ONS = Office of National Statistics. QPR = 
Questionnaire for Personal Recovery. RCT = radomised controlled trial.
Plappert H et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2021.0033
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participants across around 56 practice clusters. This assumes an mean average of 6 participants per 
cluster, 20% drop out at the individual participant level, and 10% drop out at the cluster level.
The trial protocol included an interim blinded review of the assumptions underpinning the original 
sample size calculation. The pre- specified review was based on data from 39 participants with complete 
baseline and follow- up primary outcome data, and explored the a priori assumption of a correlation of 
0.5 between baseline and follow- up MANSA scores, but which had not been included in the original 
sample size calculation. From the blinded review, the point estimate of this correlation was 0.69 (80% 
confidence interval [CI] = 0.56 to 0.79), and, as such, it was deemed appropriate to conservatively 
allow for a correlation of 0.5 in a revised sample size calculation. Retaining all the other original 
assumptions of the sample size calculation indicated a recruitment target of 270 participants from 
around 45 GP practices, to achieve 90% power or 204 participants from around 34 GP practices to 
achieve 80% power, to detect the pre- specified between- group difference of 0.45 units. In December 
2019, both the DMC and TSC approved a revised recruitment target of 270 participants.
In January 2020, the study funder mandated that trial recruitment be terminated at the end of 
February 2020, in line with the recruitment timescales for the funded programme and based on 
evidence that recruitment numbers would likely provide approximately 80% power (achieving 270 
participants would have required a significant costed extension). Following the funder’s decision, the 
aim was to recruit 204 participants, from approximately 34 GP practices, to achieve 80% power to 
detect the pre- specified target difference of 0.45 units, based on the underpinning assumptions of 
SD of 0.9, mean cluster size of 6 participants, coefficient of variation of 0.74, intra- cluster correlation 
of 0.05, correlation between baseline and follow- up MANSA scores of 0.5, and allowing for 20% drop 
out at the individual participant level and 10% drop out at the cluster level following randomisation.
Serious adverse events
The risk of harm associated with trial procedures and the intervention are considered to be low, and 
therefore only serious adverse events (SAEs) are being collected. Investigators collate and report all 
SAEs that meet the following definition:
Any untoward medical occurrence or effect that:
• results in death;
• is life threatening;
• requires hospitalisation or prolongation of existing hospitalisation;
• results in persistent or significant disability or incapacity;
• is a congenital abnormality or birth defect; or
• is otherwise considered medically significant by the investigator. This will include:
 – crisis care (contact with Home Treatment Team), and
 – self- harm.
Planned hospital admissions or attendances for less than 24 hours are not reported. SAEs are 
recorded in the source data and on the case report form, and are reported to the trials office within 
24 hours of awareness of the event by completing and submitting an SAE form.
Data management and statistical analysis
Processes to ensure the accuracy of the data are detailed in the trial data management plan. Coding 
and validation have been agreed between the trial team, statistician, and the trial programmer.
Data from case report forms are entered onto the database by researchers and/or CTU staff 
in accordance with working instructions, and data queries are managed through the use of data 
clarification forms. Corrections which are self- evident will be agreed with the Chief Investigator (CI).
Statistical analyses are pre- specified and a detailed statistical analysis plan will be agreed by the 
DMC and signed off by the independent TSC statistician prior to locking of the database. This plan will 
be available from the authors on request. Results will be reported in line with relevant Consolidated 
Standards of Reporting Trials (CONSORT) guidelines.14–16 The primary analyses will be undertaken 
according to a modified intention- to- treat principle, including all participants who are randomised 
and who provide valid outcome data at baseline and 10- month follow- up. For the primary outcome, 
multiple imputation will be undertaken in order to present a sensitivity analysis of the full intention- 
to- treat population.
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The primary analysis of the primary outcome will be undertaken blinded to allocated group, and 
will involve comparison of the change in overall MANSA score between baseline assessment and 
10- month follow- up between allocated groups. The comparison will be undertaken using a mixed- 
effects linear regression model adjusted for baseline MANSA score, as well as the stratification factors 
(region and practice size), and including a random effect term for GP practice to account for the 
hierarchical structure of the data induced by the cluster randomisation. Results without adjustment for 
the stratification variables will also be presented. Model assumptions will be checked and appropriate 
data transformations sought if required. Continuous secondary outcomes will be analysed similarly. 
All treatment effect estimates will be presented alongside 95% CIs. Additional secondary analyses of 
the primary outcome will be considered to explore the effect of intervention fidelity and Care Partner 
availability on the estimated treatment effect, using Complier Average Causal Effect and per- protocol 
analyses.
Health economics evaluation
The economic evaluation will assess the costs, outcomes and relative cost- effectiveness of the 
intervention from the perspective of health and social care services (costs) and patients (health 
benefits), over the 10- month time horizon of the trial. The primary measure of benefit will be the 
quality adjusted life years, derived from the EQ- 5D- 5L, and published utility values recommended by 
NICE at the time of analysis.
NHS and social care costs will be calculated using the participant questionnaire data and data from 
the audit of primary care records. This includes hospital inpatient and outpatient services, community- 
based mental health and social care services and primary care services. Service use data will be 
combined with the most recent published national unit costs to estimate health and social care costs. 
Regression analysis will be used to extrapolate the 3- month participant reported service use data to 
the 10- month time horizon. This will be combined with the audit data to estimate a total cost for each 
participant.
The cost and health benefit data will be analysed by treatment allocated and include data for all 
participants whether or not they completed planned care. Single imputation will be used for missing 
baseline measures of cost, utility, and clinical indicators,17 but not missing demographic data. An 
indicator for missing demographic data will be used. The final imputation strategy will depend on the 
pattern of missingness. If the data approximate Missing at Random or Missing Completely at Random, 
multiple imputation from available data will be used, as recommended by Faria et al.18
Regression analysis will estimate net costs and net quality adjusted life years of collaborative 
care (compared to treatment as usual). Incremental cost- effectiveness ratios will be calculated. 
Bootstrapping will be used to generate cost- effectiveness acceptability curves, the probability 
collaborative care is cost- effective, and net benefit statistics.
Sensitivity analysis will explore the impact on the conclusions of alternative health benefit measures, 
alternative methods of estimating costs, and alternative methods to account for missing data.
Process evaluation
The realist process evaluation will assess fidelity to the model, and develop an understanding of how 
the intervention does or does not work. It builds on earlier work7,8 and runs in parallel to the trial.
The key objectives are:
1. to assess the fidelity of the intervention during delivery against the PARTNERS2 theory 
represented by the logic model (Figure 1) and operationalised by the PARTNERS2 manuals;
2. to assess how any changes in the understanding and behaviour of the Care Partners over the 
duration of the trial were influenced by the initial and top- up training, supervision sessions, and 
tape- assisted recall;
3. to achieve a more in- depth understanding of how the intervention works or does not work in 
comparison to the programme theory, and how it can be implemented in different contexts;
4. to develop implementation recommendations, especially in relation to acceptability, adoption, 
feasibility, fidelity, and penetration; and
5. to understand the impact of delivering the intervention under COVID-19 on the above.
Data will be collected in the following ways:
• semi- structured interviews with service users, carers, practitioners, and PARTNERS2 researchers;
Plappert H et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2021.0033
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• audio recordings of clinical sessions and follow- up interviews with participant and Care Partner;
• Care Partner reflective practice logs;
• researcher observations and field notes;
• process of care data recording, for example, the nature and frequency of practitioner contact 
and liason with other bodies;
• survey of fidelity of service received; and
• contextual questionnaires detailing characteristics of practitioners and practices.
In order to encompass the complexity of the PARTNERS2 intervention, the authors are conducting 
longitudinal, integrated mixed- methods case studies at two levels:
• service user level; and
• Care Partner level.
This realist process evaluation will provide both a refined programme theory and produce 
evidence that can inform effective interventions for implementation.19
Trial management and independent oversight committees
The Trial Management Group (CI/principal investigator [PI]), trial team, members of Peninsula Clinical 
Trials Unit (PenCTU)) meet regularly to ensure successful implementation of the trial. The TSC meets 
annually. The DMC reviewed blinded data and were asked to recommend whether or not, based on 
the accruing trial data together with any emerging evidence from other relevant research, recruitment 
should continue. The DMC also considered the detailed blinded sample size review. The TSC and 
DMC operate in accordance with trial specific charters.
Ethics
The trial is conducted in accordance with the UK Policy Framework for Health and Social Care 
Research, the Data Protection Act 2018, and the Principles of Good Clinical Practice. The protocol and 
subsequent amendments were ratified by the sponsor before being submitted to and approved by the 
West Midlands- Edgbaston Research Ethics Committee prior to circulation (reference: 14/WM/0052).
Consent and confidentiality
Consent was obtained by the programme grant research team and clinical research network- funded 
staff. Participant information that identifies the participants by name (for example, consent forms, 
contact forms) will be kept in lockable cabinets or electronic secure data storage. This will be 
stored separately from trial data, which will be anonymous and confidential. There will be limits to 
confidentiality where data indicates a risk of harm to the participant or others. At the end of the trial, 
data will be moved to secure storage for at least 10 years, after which it will be destroyed.
Dissemination
Results will be disseminated in peer review journals and local, national, and international conferences. 
The final report will be submitted to the funder. Plain language summaries will be disseminated to 
participants in consultation with the LEAPs. Authors will be recognised in the accordance with the 




Collaborative care is a system that offers a new way of supporting people with ongoing mental health 
needs, that may improve primary care engagement and healthcare access impacting on physical 
health, mental health, and social recovery, for example, returning to vocational and social roles. The 
vast majority of work on collaborative care has been developed and evaluated in the US, where the 
nature of service user populations and of service use differ from the way the UK fund, structure, and 
use the NHS in England. While there is considerable evidence for its effectiveness, this research has 
largely been carried out with populations with non- psychotic disorders, of mild to moderate severity, 
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and less functional impairment than experienced by people with schizophrenia or bipolar. PARTNERS2 
is the first trial of that model to be carried out in the UK.
Strengths and limitations
• The study is a four- area cluster RCT of a collaborative care coaching intervention for individuals 
with psychosis; it will provide much- needed evidence of what works for this population, whose 
needs are often not met.
• The components of the intervention and trial procedures were developed with extensive 
feasibility work. Primary and secondary outcomes have been selected cover a broad range of 
outcome domains that could be impacted by the complex intervention.
• The study adopts a flexible and pragmatic approach to recruitment and data collection to try to 
overcome the challenges of varied NHS services and the COVID-19 pandemic.
• The lack of blinding of researchers collecting study data is a limitation of the study design.
Implication for research and practice
The aim of the study is to provide an evidence based (social/mental health, effectiveness, and 
economic) rationale as to how and why the PARTNERS2 intervention should be commissioned.
Funding
PARTNERS2 is funded by the National Institute for Health Research (NIHR) under its Programme 
Grant for Applied Research Programme (grant number: RP- PG-200625). This research was also sup-
ported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West 
Peninsula at the Royal Devon and Exeter NHS Foundation Trust. The views expressed are those of 
the author(s) and not necessarily those of the National Health Service (NHS), NIHR or the Depart-
ment of Health. The funder had no role in the design of this study and will not have any role during 
execution, analysis, interpretation of findings or decision to submit results.
Ethical approval
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